IDRx
2 known investors
IDRx discovers, develops and delivers medicines and vaccines focused on cancer, HIV, respiratory diseases, and infectious diseases. The company aims to positively impact the health of 2.5 billion people by the end of the decade.
Investors · 2
In the news
- IDRx Raises $120M in Series B Financing | Precision Medicine Onlineprecisionmedicineonline.com · 2024
- IDRx raises $120M for targeted GIST drug following leadership changeendpoints.news · 2024
- IDRx raises $120m to fund gastric tumour trials for lead TKI therapypharmaceutical-technology.com · 2024
- IDRx - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2022
- IDRx raises $122M to block gastrointestinal stromal tumor, or GIST - Boston Business Journalbizjournals.com · 2022
- IDRx Launches with $122 Million Series A Financing to Treat Cancer with Purpose-Built Precision Combination Therapiesbusinesswire.com · 2022